BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $ABBV readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04704921-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~ATMOSPHERE readout (P2/3) · AbbVie $ABBV
DESCRIPTION:Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Th
 erapy Administered Via Subretinal Delivery One Time in Participants With n
 AMD\n\nPrimary completion date: 2026-12 (estimated) — month only\, shown
  on the 1st\nOriginally planned: 2023-03 (+45.0 months)\nPhase 2/3 · Eye 
 · AMD\, nAMD\, Wet Age-related Macular Degeneration\nEnrollment: 671 · S
 ites: 89\n\nPrimary completion = last participant's primary-endpoint data 
 collected\; topline results usually follow weeks to months later. Sponsor-
 reported\, often an estimate. Not investment advice.\n\nhttps://trialsonar
 .netlify.app/radar.html?nct=NCT04704921\nhttps://clinicaltrials.gov/study/
 NCT04704921
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04704921
CATEGORIES:Eye,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06107413-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~ABBV-400 readout (P2) · AbbVie $ABBV
DESCRIPTION:Study to Assess Adverse Events and Change in Disease Activity i
 n Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-40
 0 With Unresectable Metastatic Colorectal …\n\nPrimary completion date: 
 2026-12 (estimated) — month only\, shown on the 1st\nOriginally planned:
  2026-10-16 (+1.5 months)\nPhase 2 · Oncology · Unresectable Metastatic 
 Colorectal Cancer\nEnrollment: 280 · Sites: 64\n\nPrimary completion = la
 st participant's primary-endpoint data collected\; topline results usually
  follow weeks to months later. Sponsor-reported\, often an estimate. Not i
 nvestment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT0610
 7413\nhttps://clinicaltrials.gov/study/NCT06107413
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06107413
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06468228-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~Intrepid readout (P3) · AbbVie $ABBV
DESCRIPTION:A Study to Assess Disease Activity and Safety of Lutikizumab in
  Adult and Adolescent Participants With Moderate to Severe Hidradenitis Su
 ppurativa\n\nPrimary completion date: 2026-12 (estimated) — month only\,
  shown on the 1st\nPhase 3 · Infectious · Hidradenitis Suppurativa\nEnro
 llment: 1400 · Sites: 279\n\nPrimary completion = last participant's prim
 ary-endpoint data collected\; topline results usually follow weeks to mont
 hs later. Sponsor-reported\, often an estimate. Not investment advice.\n\n
 https://trialsonar.netlify.app/radar.html?nct=NCT06468228\nhttps://clinica
 ltrials.gov/study/NCT06468228
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06468228
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109272-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:~LIVIGNO-2 readout (P2/3) · AbbVie $ABBV
DESCRIPTION:A Study to Assess the Dose\, Adverse Events\, and Change in Dis
 ease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combinat
 ion With Budigalimab as an IV Solution in Ad…\n\nPrimary completion date
 : 2027-01 (estimated) — month only\, shown on the 1st\nOriginally planne
 d: 2030-06-29 (-41.9 months)\nPhase 2/3 · Oncology · Hepatocellular Carc
 inoma\nEnrollment: 89 · Sites: 37\n\nPrimary completion = last participan
 t's primary-endpoint data collected\; topline results usually follow weeks
  to months later. Sponsor-reported\, often an estimate. Not investment adv
 ice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06109272\nhttps:/
 /clinicaltrials.gov/study/NCT06109272
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06109272
CATEGORIES:Oncology,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06701331-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:~Start Up Japan readout (P3) · AbbVie $ABBV
DESCRIPTION:Safety and Efficacy of Upadacitinib in Combination With Topical
  Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan 
 With Moderate to Severe Atopic Dermatitis\n\nPrimary completion date: 2027
 -01 (estimated) — month only\, shown on the 1st\nPhase 3 · Immuno · At
 opic Dermatitis\nEnrollment: 99 · Sites: 25\n\nPrimary completion = last 
 participant's primary-endpoint data collected\; topline results usually fo
 llow weeks to months later. Sponsor-reported\, often an estimate. Not inve
 stment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT0670133
 1\nhttps://clinicaltrials.gov/study/NCT06701331
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06701331
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06365853-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:~Mirvetuximab Soravtansine readout (P2) · AbbVie $ABBV
DESCRIPTION:A Study of Ocular Toxicity Evaluation and Mitigation During Tre
 atment With Mirvetuximab Soravtansine in Participants With Recurrent Ovari
 an Cancer With High Folate Receptor-Alpha …\n\nPrimary completion date: 
 2027-02 (estimated) — month only\, shown on the 1st\nOriginally planned:
  2026-05-26 (+8.2 months)\nPhase 2 · Oncology · Recurrent Ovarian Cancer
 \, Folate Receptor-Alpha Positive\nEnrollment: 108 · Sites: 41\n\nPrimary
  completion = last participant's primary-endpoint data collected\; topline
  results usually follow weeks to months later. Sponsor-reported\, often an
  estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.
 html?nct=NCT06365853\nhttps://clinicaltrials.gov/study/NCT06365853
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06365853
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06524635-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:~Lutikizumab readout (P2) · AbbVie $ABBV
DESCRIPTION:A Study to Assess Molecular Changes in Adult Participants With 
 Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Ato
 pic Dermatitis Receiving Subcutaneous Inje…\n\nPrimary completion date: 
 2027-02 (estimated) — month only\, shown on the 1st\nPhase 2 · Infectio
 us · Hidradenitis Suppurativa\, Atopic Dermatitis\nEnrollment: 60 · Site
 s: 2\n\nPrimary completion = last participant's primary-endpoint data coll
 ected\; topline results usually follow weeks to months later. Sponsor-repo
 rted\, often an estimate. Not investment advice.\n\nhttps://trialsonar.net
 lify.app/radar.html?nct=NCT06524635\nhttps://clinicaltrials.gov/study/NCT0
 6524635
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06524635
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06602479-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:~AURORA readout (P2) · AbbVie $ABBV
DESCRIPTION:A Study to Investigate the Safety and Efficacy of MEDI0618 Comp
 ared to Placebo in Adult Participants With Episodic Migraine\n\nPrimary co
 mpletion date: 2027-02 (estimated) — month only\, shown on the 1st\nOrig
 inally planned: 2026-09-02 (+5.0 months)\nPhase 2 · Neuro · Migraine\nEn
 rollment: 309 · Sites: 71\n\nPrimary completion = last participant's prim
 ary-endpoint data collected\; topline results usually follow weeks to mont
 hs later. Sponsor-reported\, often an estimate. Not investment advice.\n\n
 https://trialsonar.netlify.app/radar.html?nct=NCT06602479\nhttps://clinica
 ltrials.gov/study/NCT06602479
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06602479
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972446-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:~Lutikizumab readout (P2) · AbbVie $ABBV
DESCRIPTION:A Study to Evaluate Different Targeted Therapies for Patients W
 ith Rheumatoid Arthritis\n\nPrimary completion date: 2027-02 (estimated) 
 — month only\, shown on the 1st\nPhase 2 · Immuno · Rheumatoid Arthrit
 is\nEnrollment: 180 · Sites: 96\n\nPrimary completion = last participant'
 s primary-endpoint data collected\; topline results usually follow weeks t
 o months later. Sponsor-reported\, often an estimate. Not investment advic
 e.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06972446\nhttps://c
 linicaltrials.gov/study/NCT06972446
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06972446
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04777357-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~3112 Ped BPD readout (P3) · AbbVie $ABBV
DESCRIPTION:A Study to Assess Change in Disease Activity and Adverse Events
  (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatr
 ic Participants Participants (10 to 17 Yea…\n\nPrimary completion date: 
 2027-03 (estimated) — month only\, shown on the 1st\nOriginally planned:
  2024-01-31 (+37.0 months)\nPhase 3 · Neuro · Depression\, Bipolar I Dis
 order\nEnrollment: 380 · Sites: 81\n\nPrimary completion = last participa
 nt's primary-endpoint data collected\; topline results usually follow week
 s to months later. Sponsor-reported\, often an estimate. Not investment ad
 vice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT04777357\nhttps:
 //clinicaltrials.gov/study/NCT04777357
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04777357
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05843643-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~SELECT-SLE readout (P3) · AbbVie $ABBV
DESCRIPTION:Program to Assess Adverse Events and Change in Disease Activity
  of Oral Upadacitinib in Adult Participants With Moderate to Severe System
 ic Lupus Erythematosus\n\nPrimary completion date: 2027-03 (estimated) —
  month only\, shown on the 1st\nOriginally planned: 2026-10-02 (+4.9 month
 s)\nPhase 3 · Immuno · Systemic Lupus Erythematosus\nEnrollment: 1014 ·
  Sites: 369\n\nPrimary completion = last participant's primary-endpoint da
 ta collected\; topline results usually follow weeks to months later. Spons
 or-reported\, often an estimate. Not investment advice.\n\nhttps://trialso
 nar.netlify.app/radar.html?nct=NCT05843643\nhttps://clinicaltrials.gov/stu
 dy/NCT05843643
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05843643
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06063967-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~AFFIRM readout (P3) · AbbVie $ABBV
DESCRIPTION:A Study to Assess Adverse Events and Change in Disease Activity
  of Risankizumab Subcutaneous Induction Treatment for Moderately to Severe
 ly Active Crohn's Disease.\n\nPrimary completion date: 2027-03 (estimated)
  — month only\, shown on the 1st\nOriginally planned: 2026-03-27 (+11.1 
 months)\nPhase 3 · GI·Renal·Heme · Crohn's Disease\nEnrollment: 289 ·
  Sites: 179\n\nPrimary completion = last participant's primary-endpoint da
 ta collected\; topline results usually follow weeks to months later. Spons
 or-reported\, often an estimate. Not investment advice.\n\nhttps://trialso
 nar.netlify.app/radar.html?nct=NCT06063967\nhttps://clinicaltrials.gov/stu
 dy/NCT06063967
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06063967
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632951-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~LIVIGNO-3 readout (P2) · AbbVie $ABBV
DESCRIPTION:Study to Evaluate Adverse Events and Change in Disease Activity
  When Intravenously (IV) Infused Livmoniplimab is Used in Combination With
  IV Infused Budigalimab in Adult Participa…\n\nPrimary completion date: 
 2027-03 (estimated) — month only\, shown on the 1st\nOriginally planned:
  2028-08-08 (-17.3 months)\nPhase 2 · Oncology · Urothelial Carcinoma\nE
 nrollment: 150 · Sites: 37\n\nPrimary completion = last participant's pri
 mary-endpoint data collected\; topline results usually follow weeks to mon
 ths later. Sponsor-reported\, often an estimate. Not investment advice.\n\
 nhttps://trialsonar.netlify.app/radar.html?nct=NCT06632951\nhttps://clinic
 altrials.gov/study/NCT06632951
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06632951
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220460-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~ABBV-932 readout (P2) · AbbVie $ABBV
DESCRIPTION:Study to Assess the Adverse Events of Oral ABBV-932 in Adult Pa
 rticipants With Depressive Episodes Associated With Bipolar I or II Disord
 er\n\nPrimary completion date: 2027-03 (estimated) — month only\, shown 
 on the 1st\nPhase 2 · Neuro · Bipolar I or II Disorder\nEnrollment: 84 
 · Sites: 49\n\nPrimary completion = last participant's primary-endpoint d
 ata collected\; topline results usually follow weeks to months later. Spon
 sor-reported\, often an estimate. Not investment advice.\n\nhttps://trials
 onar.netlify.app/radar.html?nct=NCT07220460\nhttps://clinicaltrials.gov/st
 udy/NCT07220460
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07220460
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05445778-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:~GLORIOSA readout (P3) · AbbVie $ABBV
DESCRIPTION:Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab a
 s Maintenance in Platinum-sensitive Epithelial Ovarian\, Fallopian Tube\, 
 or Peritoneal Cancer\n\nPrimary completion date: 2027-04 (estimated) — m
 onth only\, shown on the 1st\nPhase 3 · Oncology · Ovarian Cancer\, Peri
 toneal Cancer\, Fallopian Tube Cancer\nEnrollment: 520 · Sites: 264\n\nPr
 imary completion = last participant's primary-endpoint data collected\; to
 pline results usually follow weeks to months later. Sponsor-reported\, oft
 en an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/r
 adar.html?nct=NCT05445778\nhttps://clinicaltrials.gov/study/NCT05445778
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05445778
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05125302-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:~Ubro Peds readout (P3) · AbbVie $ABBV
DESCRIPTION:Study to Assess Adverse Events and Disease Activity of Oral Ubr
 ogepant Tablets for the Acute Treatment of Migraine in Children and Adoles
 cents (Ages 6-17)\n\nPrimary completion date: 2027-05 (estimated) — mont
 h only\, shown on the 1st\nOriginally planned: 2026-02-05 (+14.8 months)\n
 Phase 3 · Neuro · Migraine\nEnrollment: 1059 · Sites: 129\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.htm
 l?nct=NCT05125302\nhttps://clinicaltrials.gov/study/NCT05125302
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05125302
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06718101-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:~EMBARK readout (P2) · AbbVie $ABBV
DESCRIPTION:A Study to Evaluate the Effectiveness and Safety of Treatments\
 , Either Alone or in Combination\, for the Treatment of Moderate to Severe
  Atopic Dermatitis\n\nPrimary completion date: 2027-05 (estimated) — mon
 th only\, shown on the 1st\nPhase 2 · Immuno · Atopic Dermatitis\nEnroll
 ment: 83 · Sites: 30\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://trialsonar.netlify.app/radar.html?nct=NCT06718101\nhttps://clinicaltria
 ls.gov/study/NCT06718101
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06718101
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02899052-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~Carfilzomib readout (P2) · AbbVie $ABBV
DESCRIPTION:Study of Venetoclax in Combination With Carfilzomib and Dexamet
 hasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)\n
 \nPrimary completion date: 2027-06 (estimated) — month only\, shown on t
 he 1st\nOriginally planned: 2020-03 (+87.0 months)\nPhase 2 · Oncology ·
  Multiple Myeloma\nEnrollment: 120 · Sites: 32\n\nPrimary completion = la
 st participant's primary-endpoint data collected\; topline results usually
  follow weeks to months later. Sponsor-reported\, often an estimate. Not i
 nvestment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT0289
 9052\nhttps://clinicaltrials.gov/study/NCT02899052
URL:https://trialsonar.netlify.app/radar.html?nct=NCT02899052
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03006068-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:~U-ACTIVATE readout (P3) · AbbVie $ABBV
DESCRIPTION:A Study to Evaluate the Long-Term Safety and Efficacy of Upadac
 itinib (ABT-494) in Participants With Ulcerative Colitis (UC)\n\nPrimary c
 ompletion date: 2027-07 (estimated) — month only\, shown on the 1st\nOri
 ginally planned: 2027-01 (+5.9 months)\nPhase 3 · GI·Renal·Heme · Ulce
 rative Colitis (UC)\nEnrollment: 950 · Sites: 492\n\nPrimary completion =
  last participant's primary-endpoint data collected\; topline results usua
 lly follow weeks to months later. Sponsor-reported\, often an estimate. No
 t investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT0
 3006068\nhttps://clinicaltrials.gov/study/NCT03006068
URL:https://trialsonar.netlify.app/radar.html?nct=NCT03006068
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04333576-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:~ELARIS EM-COC readout (P3) · AbbVie $ABBV
DESCRIPTION:Study Of Oral Elagolix Tablets In Combination With Combined Ora
 l Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult 
 Female Participants With Endometriosis And…\n\nPrimary completion date: 
 2027-07 (estimated) — month only\, shown on the 1st\nOriginally planned:
  2024-09-02 (+33.9 months)\nPhase 3 · GI·Renal·Heme · Endometriosis\nE
 nrollment: 800 · Sites: 179\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://trialsonar.netlify.app/radar.html?nct=NCT04333576\nhttps://clini
 caltrials.gov/study/NCT04333576
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04333576
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04401748-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:~Verona readout (P3) · AbbVie $ABBV
DESCRIPTION:Study Of Venetoclax Tablet With Intravenous or Subcutaneous Aza
 citidine to Assess Change in Disease Activity In Adult Participants With N
 ewly Diagnosed Higher-Risk Myelodysplastic…\n\nPrimary completion date: 
 2027-07 (estimated) — month only\, shown on the 1st\nOriginally planned:
  2025-01-26 (+29.1 months)\nPhase 3 · Oncology · Myelodysplastic Syndrom
 e (MDS)\nEnrollment: 531 · Sites: 220\n\nPrimary completion = last partic
 ipant's primary-endpoint data collected\; topline results usually follow w
 eeks to months later. Sponsor-reported\, often an estimate. Not investment
  advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT04401748\nhtt
 ps://clinicaltrials.gov/study/NCT04401748
URL:https://trialsonar.netlify.app/radar.html?nct=NCT04401748
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03844048-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~Venetoclax readout (P3) · AbbVie $ABBV
DESCRIPTION:An Extension Study of Venetoclax for Subjects Who Have Complete
 d a Prior Venetoclax Clinical Trial\n\nPrimary completion date: 2027-08 (e
 stimated) — month only\, shown on the 1st\nOriginally planned: 2024-12-2
 1 (+31.3 months)\nPhase 3 · Oncology · Chronic Lymphocytic Leukemia\, Ac
 ute Myeloid Leukemia\, Multiple Myeloma\nEnrollment: 165 · Sites: 56\n\nP
 rimary completion = last participant's primary-endpoint data collected\; t
 opline results usually follow weeks to months later. Sponsor-reported\, of
 ten an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/
 radar.html?nct=NCT03844048\nhttps://clinicaltrials.gov/study/NCT03844048
URL:https://trialsonar.netlify.app/radar.html?nct=NCT03844048
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614192-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~Telisotuzumab Adizutecan readout (P2) · AbbVie $ABBV
DESCRIPTION:A Study Assessing Adverse Events and Disease Activity of Intrav
 enously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c
 -Met Protein Above Cutoff Level Above Refr…\n\nPrimary completion date: 
 2027-08 (estimated) — month only\, shown on the 1st\nOriginally planned:
  2029-04-06 (-20.2 months)\nPhase 2 · Oncology · Metastatic Colorectal C
 ancer\nEnrollment: 74 · Sites: 51\n\nPrimary completion = last participan
 t's primary-endpoint data collected\; topline results usually follow weeks
  to months later. Sponsor-reported\, often an estimate. Not investment adv
 ice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06614192\nhttps:/
 /clinicaltrials.gov/study/NCT06614192
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06614192
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880744-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~REVAMP readout (P3) · AbbVie $ABBV
DESCRIPTION:A Study to Assess the Change in Disease Activity in Adult Parti
 cipants With Moderate to Severe Ulcerative Colitis Treated With Risankizum
 ab Compared to Vedolizumab\n\nPrimary completion date: 2027-08 (estimated)
  — month only\, shown on the 1st\nOriginally planned: 2028-09 (-13.0 mon
 ths)\nPhase 3 · GI·Renal·Heme · Ulcerative Colitis\nEnrollment: 573 ·
  Sites: 270\n\nPrimary completion = last participant's primary-endpoint da
 ta collected\; topline results usually follow weeks to months later. Spons
 or-reported\, often an estimate. Not investment advice.\n\nhttps://trialso
 nar.netlify.app/radar.html?nct=NCT06880744\nhttps://clinicaltrials.gov/stu
 dy/NCT06880744
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06880744
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03345823-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~U-ENDURE readout (P3) · AbbVie $ABBV
DESCRIPTION:A Maintenance and Long-Term Extension Study of the Efficacy and
  Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who
  Completed the Studies M14-431 or M14-433\n\nPrimary completion date: 2027
 -09 (estimated) — month only\, shown on the 1st\nOriginally planned: 201
 9-01-30 (+103.0 months)\nPhase 3 · GI·Renal·Heme · Crohn's Disease\nEn
 rollment: 747 · Sites: 466\n\nPrimary completion = last participant's pri
 mary-endpoint data collected\; topline results usually follow weeks to mon
 ths later. Sponsor-reported\, often an estimate. Not investment advice.\n\
 nhttps://trialsonar.netlify.app/radar.html?nct=NCT03345823\nhttps://clinic
 altrials.gov/study/NCT03345823
URL:https://trialsonar.netlify.app/radar.html?nct=NCT03345823
CATEGORIES:GI·Renal·Heme,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06257875-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~Lutikizumab readout (P2) · AbbVie $ABBV
DESCRIPTION:A Study to Assess Adverse Events and Change in Disease Activity
  From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Particip
 ants With Active Ulcerative Colitis\n\nPrimary completion date: 2027-09 (e
 stimated) — month only\, shown on the 1st\nOriginally planned: 2027-04-2
 6 (+4.2 months)\nPhase 2 · GI·Renal·Heme · Ulcerative Colitis\nEnrollm
 ent: 156 · Sites: 191\n\nPrimary completion = last participant's primary-
 endpoint data collected\; topline results usually follow weeks to months l
 ater. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttp
 s://trialsonar.netlify.app/radar.html?nct=NCT06257875\nhttps://clinicaltri
 als.gov/study/NCT06257875
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06257875
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06345339-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~Armour Thyroid readout (P2/3) · AbbVie $ABBV
DESCRIPTION:A Study to Assess the Safety and Efficacy of Oral Armour Thyroi
 d Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in 
 Adult Participants\n\nPrimary completion date: 2027-09 (estimated) — mon
 th only\, shown on the 1st\nOriginally planned: 2028-06-03 (-9.1 months)\n
 Phase 2/3 · Cardio-Met · Hypothyroidism\nEnrollment: 2701 · Sites: 139\
 n\nPrimary completion = last participant's primary-endpoint data collected
 \; topline results usually follow weeks to months later. Sponsor-reported\
 , often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.
 app/radar.html?nct=NCT06345339\nhttps://clinicaltrials.gov/study/NCT063453
 39
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06345339
CATEGORIES:Cardio-Met,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276997-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~Icalcaprant readout (P2) · AbbVie $ABBV
DESCRIPTION:A Study to Assess Change in Disease Activity and Adverse Events
  of Oral Icalcaprant in Adult Participants With Major Depressive Disorder\
 n\nPrimary completion date: 2027-09 (estimated) — month only\, shown on 
 the 1st\nPhase 2 · Neuro · Major Depressive Disorder\nEnrollment: 195 ·
  Sites: 33\n\nPrimary completion = last participant's primary-endpoint dat
 a collected\; topline results usually follow weeks to months later. Sponso
 r-reported\, often an estimate. Not investment advice.\n\nhttps://trialson
 ar.netlify.app/radar.html?nct=NCT07276997\nhttps://clinicaltrials.gov/stud
 y/NCT07276997
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07276997
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417775-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~UBRO MM readout (P3) · AbbVie $ABBV
DESCRIPTION:Study of Oral Ubrogepant to Assess Adverse Events and Change in
  Disease Activity in Adult Participants With Menstrual Migraine\n\nPrimary
  completion date: 2027-11 (estimated) — month only\, shown on the 1st\nO
 riginally planned: 2027-09-08 (+1.8 months)\nPhase 3 · Neuro · Migraine\
 nEnrollment: 496 · Sites: 106\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06417775\nhttps://cli
 nicaltrials.gov/study/NCT06417775
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06417775
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06696755-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~Icalcaprant readout (P2) · AbbVie $ABBV
DESCRIPTION:A Study to Assess Adverse Events and Change in Disease Activity
  of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder\n
 \nPrimary completion date: 2027-11 (estimated) — month only\, shown on t
 he 1st\nOriginally planned: 2026-10-29 (+12.1 months)\nPhase 2 · Neuro ·
  Bipolar I Disorder\, Bipolar II Disorder\nEnrollment: 195 · Sites: 33\n\
 nPrimary completion = last participant's primary-endpoint data collected\;
  topline results usually follow weeks to months later. Sponsor-reported\, 
 often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.ap
 p/radar.html?nct=NCT06696755\nhttps://clinicaltrials.gov/study/NCT06696755
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06696755
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
